Ipsen (CHIX:IPNP) YoY EPS Growth: 21.50% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IPNP Ipsen SA CHIX:IPNP
94 GF Score
Price €158.95
GF Value €134.16
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ipsen YoY EPS Growth?

Ipsen CHIX:IPNP 94 YoY EPS Growth is 21.50% as of Jun. 2026. GuruFocus rates CHIX:IPNP with a GF Score™ of 94/100 and a GF Value™ of €134.16 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Ipsen's YoY EPS Growth for the quarter that ended in Jun. 2026 was 21.50%.

Ipsen's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was €4.86.

Ipsen YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Ipsen's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen YoY EPS Growth Chart

Ipsen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.11 0.64 -1.02 -46.31 28.19

Ipsen Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.30 -74.54 43.88 -3.65 21.50
CHIX:IPNP
94GF Score
Ipsen SA CHIX:IPNP
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipsen YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Ipsen's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(5.32-4.15)/ | 4.15 |
=28.19 %

Ipsen's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(4.86-4)/ | 4 |
=21.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 21.50% mean?
Ipsen (CHIX:IPNP) has a YoY EPS Growth of 21.50% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Ipsen and its competitors.
Is Ipsen's YoY EPS Growth too high?
Ipsen's current YoY EPS Growth is 21.50%. Overall, Ipsen has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's YoY EPS Growth compare to ZTS and UTHR?
Ipsen's YoY EPS Growth of 21.50% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Ipsen and its competitors. Ipsen's current YoY EPS Growth is 21.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (CHIX:IPNP) is currently considered Modestly Overvalued. The stock's GF Value™ is €134.16, compared to a current price of €158.95 — trading 18.5% above its estimated fair value. The current YoY EPS Growth is 21.50%. Ipsen's overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Ipsen (CHIX:IPNP), the current YoY EPS Growth is 21.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (CHIX:IPNP) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €158.95 is trading 18.5% above its estimated GF Value™ of €134.16. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for CHIX:IPNP:

  • YoY EPS Growth: 21.50%
  • GF Value™: €134.16 vs. price of €158.95 (18.5% above fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the CHIX:IPNP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
94GF Score

Get the complete analysis for CHIX:IPNP

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.95
Price
€134.16
GF Value